Alderley Park, UK – July 2025 – ImmunoKey, a UK-based biotechnology company developing a next-generation CAR T-cell platform for solid tumours, is proud to announce that it has been awarded a $225,000 grant from ScaleReady to support the development and optimisation of its manufacturing process using the G-Rex® platform.

The grant will fund critical process development work for ImmunoKey’s CARKey™ platform, a modular, trispecific CAR T-cell technology designed to overcome the major challenges that have historically limited CAR T-cell efficacy in solid tumours.

Gray Kueberuwa, CEO of ImmunoKey, commented:

“We’re delighted to receive this support from ScaleReady. Process scalability and robustness are central to ImmunoKey’s mission to bring powerful new CAR T-cell therapies to patients with solid cancers. This funding will enable us to further de-risk our manufacturing approach as we advance toward IND-enabling studies.”

The G-Rex® platform, known for its simplicity, scalability, and efficiency in expanding T cells at clinical scale, is an ideal fit for ImmunoKey’s approach and aligns with the company’s goal of building a flexible, GMP manufacturing process from the ground up that is compatible with commercialisation.

This award is a key milestone in ImmunoKey’s development, supporting the company’s aim to deliver preclinical proof-of-concept by 2026 and initiate clinical trials in ovarian cancer thereafter.

About ImmunoKey
ImmunoKey Ltd. is a UK-based biotechnology company developing next-generation CAR T-cell therapies to overcome the barriers of treating solid tumours. The company's proprietary CARKey™ platform enables multi-antigen targeting while minimising off-tumour toxicity, supported by complementary technologies AmpliT™ and ReviT™ to enhance T-cell persistence and function in the tumour microenvironment. Backed by a leadership team with proven success in cell therapy development and clinical translation, ImmunoKey is advancing a pipeline of novel immunotherapies to address critical unmet needs in oncology.

For more information, visit www.immunokey.co.uk.

For media inquiries, please contact:

ImmunoKey Ltd: Dr. Gray Kueberuwa
Email: Info@immunokey.co.uk
Website: www.immunokey.co.uk